Leclaza plus Rybrevant and Tagrisso plus platinum-based chemotherapy have shown consistent effects in Asian patients. The effects of the combination therapy of Leclaza and Tagrisso, which are non-small cell lung cancer (NSCLC) treatments, have been unveiled at the European Society for Medical Oncology (ESMO) Asia Congress 2024. ESMO Asia Congress 2024 took place over three days, starting on December 6, in Singapore.

The concurrent use of Leclaza with Rybrevant subcutaneous (SC) formulation showed non-inferior results compared to the conventional Rybrevant intravenous (IV) injection. Tagrisso plus platinum-based chemotherapy has consistently improved overall survival compared to Tagrisso monotherapy in